The DOI matches its Crossref record.
Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma
Open accessAbstract
Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland neoplasm defined by ETV6-NTRK3 gene fusion. MASC’s morphologyis not entirely specific and overlaps with other salivary gland tumors. Documenting ETV6 rearrangement is confirmatory, but most laboratories are not equipped to perform this test. As MASCs are positive for mammaglobin, immunohistochemistry could potentially replace molecular testing as a confirmatory test, but the specificity of mammaglobin has not been evaluated across a large and diverse group of salivary gland tumors. One hundred-thirty-one salivary gland neoplasms were evaluated by routine microscopy, mammaglobin immunohistochemistry, and ETV6 break-apart fluorescent in situ hybridization. The cases included 15 MASCs, 44 adenoid cystic carcinomas, 33 pleomorphic adenomas (PAs), 18 mucoepidermoid carcinomas, 10 acinic cell carcinomas, 4 adenocarcinomas not otherwise specified, 3 polymorphous low-grade adenocarcinomas, 3 salivary duct carcinomas, and 1 low-grade cribriform cystadenocarcinoma. All 15 MASCs harbored the ETV6 translocation and were strongly mammaglobin-positive. None of the 116 other tumors carried the ETV6 translocation, however mammaglobin staining was present in 1 of 1 (100%) low-grade cribriform cystadenocarcinoma, 2 of 3 (67%) polymorphous low-grade adenocarcinomas, 2 of 3 (67%) salivary duct carcinomas, 2 of 18 (11%) mucoepidermoid carcinomas, and 2 of 33 (6%) pleomorphic adenomas. Mammaglobin is highly sensitive for MASC, but immunostaining can occur in a variety of tumors that do not harbor the ETV6 translocation. Strategic use of mammaglobin immunostaining has a role in the differential diagnosis of salivary gland neoplasms, but it should not be indiscriminately used as a confirmatory test for MASC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Vaishnavi, A., Le, A. T., & Doebele, R. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0765 · Cited by 642
Okamura, R., Boichard, A., Kato, S., Sicklick, J. K., Bazhenova, L., & Kurzrock, R. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00183 · Cited by 328
Metadata
- Authors
- Bishop, J. A., Yonescu, R., Batista, D., Begum, S., Eisele, D. W., & Westra, W. H.
- Venue
- Human Pathology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 44
- Issue
- 10
- Pages
- 1982-1988
- ISSN
- 0046-8177 (ISSN-L)
- OpenAlex
- W2033586883
- Cited by
- 162
- References
- 0
- FWCI
- 12.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma. https://app.cochat.ai/papers/10.1016/j.humpath.2013.03.017
- The paper
- Bishop, J. A., Yonescu, R., Batista, D., Begum, S., Eisele, D. W., & Westra, W. H. (2013). Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma. Human Pathology. https://doi.org/10.1016/j.humpath.2013.03.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.